Advanced Elementary...
Health Care: Drugs
Elan Corp PLC (ELN: NYSE)
$14.15 0.37 | 2.69%
06/19/13 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | n.a. | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 0.94 | 0.95 | 0.98 |
| Price to Sales (TTM) | -24.40 | 5.80 | 1.42 |
| Price to Book (MRQ) | 10.30 | 5.65 | 2.41 |
| Price to Tangible Book (MRQ) | 12.03 | -5.93 | 5.08 |
| Price to Cash Flow (TTM) | -528.00 | 42.30 | 9.80 |
| Price to Free Cash Flow (TTM) | 16.00 | -20.40 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.00 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.90 | 2.30 |
| Dividend 5 Yr Growth Rate (%) | n.a. | -48.07 | 2.61 |
| Payout Ratio (TTM) | 0.00 | n.a. | 37.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | -99.90 | -4.10 | -0.90 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -100.00 | 0.40 | 2.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | n.a. | 5.32 | 3.97 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | n.a. | 18.70 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | n.a. | 18.70 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | 8.27 |
| Capital Spending - 5 Yr Growth Rate (%) | n.a. | 17.88 | 4.03 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 0.90 | 1.10 | 1.10 |
| Current Ratio (MRQ) | 1.60 | 1.90 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 1.47 | 0.73 |
| Total Debt to Equity (MRQ) | 0.88 | 1.58 | 0.86 |
| Interest Coverage (TTM) | n.a. | n.a. | 6.40 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 53.80 | 47.50 |
| Gross Margin - 5 Yr Avg | 56.60 | 53.40 | 46.90 |
| EBITD Margin (TTM) | n.a. | 20.00 | 19.40 |
| EBITD - 5 Yr Avg | -11.24 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | -18.60 | 11.30 |
| Pre-Tax Margin - 5 Yr Avg | -19.90 | -2.20 | 10.10 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | 14.70 | -0.09 | 0.08 |
| Net Profit Margin - 5 Yr Avg | -3.30 | 0.90 | 7.00 |
| Return on Assets (TTM) | -2.60 | -1.40 | 3.10 |
| Return on Assets - 5 Yr Avg | -1.50 | 0.40 | 2.50 |
| Return on Investment (TTM) | -6.20 | -1.80 | 8.20 |
| Return on Investment - 5 Yr Avg | -1.90 | 0.50 | 6.60 |
| Efficiency | |||
| Revenue/Employee (TTM) | -117,551.00 | n.a. | n.a. |
| Net Income/Employee (TTM) | -172,653.00 | n.a. | n.a. |
| Receivable Turnover (TTM) | -2.70 | 4.60 | 7.90 |
| Inventory Turnover (TTM) | n.a. | 2.50 | 7.70 |
| Asset Turnover (TTM) | -0.20 | 0.30 | 0.40 |
Portfolios with ELN
- Portfolio NameUser Type
- ContributorMost-Active Stocks for the ...
- ContributorMost-Active Stocks for the ...
- ContributorMost-Active Stocks for the ...
- ProTPG-Axon Capital
- Contributor22 Biopharma Stocks With Br...
- UserGFNN Stockdiagnostics 13
- ContributorBreakout Stocks Of The Week...
- UserGFNN Stockdiagnostics
- ContributorRelative Strength Trades fo...
- ContributorStocks At New 52-Week Highs...
Latest ELN Headlines from TheStreet
- Stock Futures Hold Gains as Inflation Appears Tame 06.18.13 | 09:06 am
- Elan Shareholder Vote Nixes Royalty Pharma Takeover -- For Now 06.17.13 | 07:06 am
- Stocks Drop Amid Fed Jitters 06.14.13 | 02:06 pm
- 3 Big Stocks on Traders' Radars 06.13.13 | 02:06 pm
- Dollar Strength Hits Oil, Gold
05.13.13 | 08:05 am - Stock Futures Lower Ahead of Retail Sales 05.13.13 | 06:05 am
- Why This Fund Manager Is Short Ziopharm 03.22.13 | 07:03 am
- SAC to Pay Record Insider Trading Penalty 03.16.13 | 11:03 am
- Dow Sets Another Record as Stocks Rise 03.11.13 | 04:03 pm
- You Have to Love a Lucrative 'Drug Deal' 02.28.13 | 06:02 am
Press Releases for ELN
- Royalty Pharma Announces Firm Offer To Acquire Elan - PR Newswire 04.15.13 | 07:04 am
- New TYSABRI Data Reaffirm Substantial Efficacy In Treatment Of People With MS And Demonstrate Stability Of Anti-JCV Antibody Status - Business Wire 03.18.13 | 07:03 am
- Elan Discloses Filing Of Share Repurchase Tender Offer Documentation - Business Wire 03.12.13 | 01:03 pm
- Elan Provides Update On Tysabri Transaction And $1bn Share Repurchase - Business Wire 03.08.13 | 04:03 pm
- Elan’s Response To Royalty Pharma Statement Of Today - Business Wire 03.06.13 | 09:03 am
- Elan Announces Further Unlocking Of Value To Benefit Shareholders - Business Wire 03.04.13 | 01:03 am
- Elan Announces The Appointment Of Mr. John Given As General Counsel - Business Wire 02.28.13 | 02:02 am
- Elan’s Response To Indication Of Interest - Business Wire 02.25.13 | 09:02 am
- Elan Provides Update Post Restructuring Announcement Of Tysabri Collaboration - Business Wire 02.22.13 | 02:02 am
- Elan Announces Filing Of Annual Report On Form 20-F For Year Ended December 31, 2012 - Business Wire 02.12.13 | 04:02 pm
Partner Headlines for ELN
- Elan Is In Play - Seeking Alpha 06.15.13 | 05:06 am
- Pre-Market Most Active for Jun 14, 2013 : NOK, HIMX, PFE, ELN, BAC, GRPN, BBRY, SCTY, SHG, SIRI, F, MYGN - NASDAQ 06.14.13 | 12:06 pm
- Pre-Market Most Active for Jun 13, 2013 : BLC, SWY, PFE, BAC, FSLR, ELN, VOD, SAN, BBRY, ERIC, SIRI, SPRD - NASDAQ 06.13.13 | 12:06 pm
- Royalty Issues Another Statement Related to Elan Suit - Benzinga 06.11.13 | 09:06 am
- Pre-Market Most Active for Jun 10, 2013 : FB, QQQ, SAN, BAC, ELN, ASX, MT, TSLA, ARMH, SFD, MU, AAPL - NASDAQ 06.10.13 | 12:06 pm
- Benzinga's M&A Chatter for Friday June 7, 2013 - Benzinga 06.09.13 | 11:06 am
- Pre-Market Most Active for Jun 7, 2013 : ELN, BAC, TIVO, TMO, PBF, QQQ, ASX, C, EQIX, FB, JRCC, SIRI - NASDAQ 06.07.13 | 12:06 pm
- Elan's Issues Response to Royalty Pharma Announcement - Benzinga 06.07.13 | 09:06 am
- Elan Rejects Royalty Offer Again - Analyst Blog - Zacks 05.24.13 | 10:05 pm
- Alkermes Earnings Beat Estimates, But Outlook Unclear - Investor's Business Daily 05.23.13 | 06:05 pm
